Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
2019
116
LTM Revenue n/a
LTM EBITDA -$168M
-$211M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cargo Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$168M.
In the most recent fiscal year, Cargo Therapeutics achieved revenue of n/a and an EBITDA of -$92.9M.
Cargo Therapeutics expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Cargo Therapeutics valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$34.6M | -$92.9M | -$176M | -$168M | XXX |
EBITDA Margin | -Infinity% | -Infinity% | -Infinity% | -Infinity% | XXX |
Net Profit | -$5.8M | -$41.0M | -$98.1M | XXX | XXX |
Net Margin | -Infinity% | -Infinity% | -Infinity% | XXX | XXX |
Net Debt | n/a | $20.0M | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Cargo Therapeutics's stock price is $4.
Cargo Therapeutics has current market cap of $165M, and EV of -$211M.
See Cargo Therapeutics trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
-$211M | $165M | XXX | XXX | XXX | XXX | $-3.54 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Cargo Therapeutics has market cap of $165M and EV of -$211M.
Cargo Therapeutics's trades at n/a LTM EV/Revenue multiple, and 1.3x LTM EBITDA.
Analysts estimate Cargo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cargo Therapeutics and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | -$211M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | XXX | XXX |
EV/EBITDA | 1.2x | XXX | XXX | XXX |
P/E | -1.0x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | 1.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCargo Therapeutics's NTM/LTM revenue growth is Infinity%
Cargo Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Cargo Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cargo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cargo Therapeutics and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | n/a | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 90% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cargo Therapeutics acquired XXX companies to date.
Last acquisition by Cargo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cargo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Cargo Therapeutics founded? | Cargo Therapeutics was founded in 2019. |
Where is Cargo Therapeutics headquartered? | Cargo Therapeutics is headquartered in United States of America. |
How many employees does Cargo Therapeutics have? | As of today, Cargo Therapeutics has 116 employees. |
Who is the CEO of Cargo Therapeutics? | Cargo Therapeutics's CEO is Ms. Gina Chapman. |
Is Cargo Therapeutics publicy listed? | Yes, Cargo Therapeutics is a public company listed on NAS. |
What is the stock symbol of Cargo Therapeutics? | Cargo Therapeutics trades under CRGX ticker. |
When did Cargo Therapeutics go public? | Cargo Therapeutics went public in 2023. |
Who are competitors of Cargo Therapeutics? | Similar companies to Cargo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Cargo Therapeutics? | Cargo Therapeutics's current market cap is $165M |
What is the current EBITDA of Cargo Therapeutics? | Cargo Therapeutics's last 12-month EBITDA is -$168M. |
What is the current EV/EBITDA multiple of Cargo Therapeutics? | Current EBITDA multiple of Cargo Therapeutics is 1.3x. |
Is Cargo Therapeutics profitable? | Yes, Cargo Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.